World's Best Scientists 2026 revealed!
Mario Boccadoro

Mario Boccadoro

D-Index & Metrics

Medicine

D-Index
110
Citations
59022
World Ranking
5454
National Ranking
172

Mario Boccadoro publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mario Boccadoro sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 958 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mario Boccadoro D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mario Boccadoro sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mario Boccadoro is affiliated with the University of Turin in Italy. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant emphasis on Hematology, Molecular Biology, and Oncology. Their scholarly output also covers subfields including Genetics and Pathology and Forensic Medicine.

The scientist's work addresses multiple topics in biomedical research. Key areas include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Cancer Treatment and Pharmacology, Chronic Lymphocytic Leukemia Research, Cancer therapeutics and mechanisms, and Chronic Myeloid Leukemia Treatments.

Frequent publication venues where Mario Boccadoro's research appears include Blood, Clinical Lymphoma Myeloma & Leukemia, HemaSphere, Journal of Clinical Oncology, and Haematologica.

Several coauthors have collaborated extensively with Mario Boccadoro, reflecting a collaborative approach in the research community. These frequent collaborators are Pieter Sonneveld, Francesca Gay, Michèle Cavo, Roman Hájek, and Meletios Α. Dimopoulos.

Among recent papers authored or coauthored by Mario Boccadoro are the following:

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2023, New England Journal of Medicine
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project, 2022, Journal of Clinical Oncology
  • Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Best Publications

  • International staging system for multiple myeloma.

    Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

    Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

  • MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

    Flavia Pichiorri;Sung Suk Suh;Marco Ladetto;Michael Kuehl

  • Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

    Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;David Irwin

  • A comparison of allografting with autografting for newly diagnosed myeloma.

    Benedetto Bruno;Marcello Rotta;Francesca Patriarca;Nicola Mordini

  • Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

    Brian G M Durie;Robert A. Kyle;Andrew Belch;William Bensinger

  • Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

    Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    M A Dimopoulos;P Moreau;E Terpos;M V Mateos

  • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

    Meletios Dimopoulos;Robert Kyle;Jean Paul Fermand;S. Vincent Rajkumar

  • Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

    Sara Bringhen;Alessandra Larocca;Davide Rossi;Maide Cavalli

  • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

    Antonio Palumbo;Sara Bringhen;Anna M. Liberati;Tommaso Caravita

  • Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

    Mandelli F;Avvisati G;Amadori S;Boccadoro M

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

Frequent Co-Authors

Antonio Palumbo
Antonio Palumbo University of Turin
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome
Michele Cavo
Michele Cavo University of Bologna
Pellegrino Musto
Pellegrino Musto University of Bari Aldo Moro
Paolo Corradini
Paolo Corradini University of Milan
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Massimo Massaia
Massimo Massaia University of Turin
Federica Cavallo
Federica Cavallo University of Turin
Roman Hájek
Roman Hájek University of Ostrava
Francesco Di Raimondo
Francesco Di Raimondo University of Catania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in alternative healthcare careers or flexible study options, several online degrees and pathways can support your goals. Many students explore nursing programs with high acceptance rates for quicker entry into the field, offering a practical route toward becoming a registered nurse. Additionally, there are best nursing schools with no TEAS or HESI exams requirement, making the admission process even more accessible for those who prefer not to take standardized tests.

If you prefer working in medical administration, accredited programs in healthcare management can be completed online, with the best accelerated healthcare administration degree programs online providing a fast track to leadership roles in clinics, hospitals, or private practices. Another in-demand choice is medical billing and coding, where best accredited medical billing and coding schools online with financial aid allow students to secure certification affordably and efficiently.

These options are ideal for students seeking flexible schedules, quicker pathways into healthcare, or alternate careers beyond traditional medical school. Exploring these online degrees can open various rewarding roles within the ever-growing healthcare sector.

Best Scientists Citing Mario Boccadoro

Trending Scientists

Recently Published Articles